Who benefits from integrative biomedical research? The socio-economic assessment method of VPHOP Dr. rer. pol. Rainer Thiel, empirica with Karl Stroetman,

Slides:



Advertisements
Similar presentations
EU eHealth Agenda Petra Wilson Director
Advertisements

Grading the Strength of a Body of Evidence on Diagnostic Tests Prepared for: The Agency for Healthcare Research and Quality (AHRQ) Training Modules for.
ICT Work Programme NCP Infoday 23 June Maria Geronymaki DG INFSO.H.2 ICT for Government & Public Services Objective.
CIRAS PROJECT OVERVIEW
© Safeguarding public health Innovation; issues for regulators, society and industry. Overview of Conference topics Alasdair Breckenridge Medicines and.
© 2006 STEP Consortium Seeding the EuroPhysiome: a roadmap to the Virtual Physiological Human Marco Viceconti STEP CONSORTIUM.
The strategic role of ICT in healthcare National strategies and micro-level implementations in Europe and Bulgaria Alexander Dobrev Communication & Technology.
Role of Pharmacoeconomics in a Developing country context Gavin Steel for Anban Pillay Cluster Manager: Health Economics National Department of Health.
Recursive Partitioning Method on Survival Outcomes for Personalized Medicine 2nd International Conference on Predictive, Preventive and Personalized Medicine.
1 Biomedical Sciences Public and Environmental Health Regenerative Medicine Translational Research.
The European Union legal framework for clinical data access: The European Union legal framework for clinical data access: potential challenges and opportunities.
A METHODOLOGY FOR MEASURING THE COST- UTILITY OF EARLY CHILDHOOD DEVELOPMENTAL INTERVENTIONS Quality of improved life opportunities (QILO)
What is “Biomedical Informatics”?. Biomedical Informatics Biomedical informatics (BMI) is the interdisciplinary field that studies and pursues.
Dorota Kilańska RN, PhD European Nursing Research Foundation (ENRF)
1 of 1 E- Health in the European Union Dr. Andrzej Rys Director for Health and Risk Assessment DG SANCO European Commission OPEN DAYS 2009 Mobility in.
Research & Innovation Horizon societal challenge 1 Open Info Day Funding Opportunities for SMEs Horizon 2020 "Health, demographic change and wellbeing"
The Knowledge Resources Guide The SUVOT Project Sustainable and Vocational Tourism Rimini, 20 October 2005.
Up and About in Care Homes The Management of Falls and Fractures in Care Homes for Older People Improvement Project 11 th September 2014 Lianne McInally.
Disease Management: High Risk Groups Principles in Practice Copyright © – Academy of Managed Care Pharmacy (AMCP)Slide 1.
IPhVWP Polish Presidency, Warsaw October 6 th 2011 Almath Spooner Irish Medicines Board Monitoring the outcome of risk minimisation activities.
Indianapolis Discovery Network for Dementia Forecasting the Future Impact of Early Detection and Management Program for Alzheimer.
Science, research and developmentEuropean Commission Chile-EC S&T Agreement Brussels, 24 September 2002 Life Sciences, Genomics and Biotechnology for Health.
Invention for Innovation (i4i) Bev Luchmun Industry Lead NISCHR
Copyright © 2008 Wolters Kluwer Health | Lippincott Williams & Wilkins Chapter 12 Undertaking Research for Specific Purposes.
MUNROS is funded by the European Commission FP7 programme MUNROS is funded by the European Commission FP7 programme,
Where to focus? Horizon 2020 'Health, demographic change and wellbeing' Open Info Day -Horizon 2020 'Health, demographic change and wellbeing' Brussels,
Summary of ICIUM Chronic Care Track Prepared by: Ricardo Perez-Cuevas Veronika Wirtz David Beran.
Transforming Community Services Commissioning Information for Community Services Stakeholder Workshop 14 October 2009 Coleen Milligan – Project Manager.
MUNROS is funded by the European Commission FP7 programme MUNROS is funded by the European Commission FP7 programme,
HTA cooperation in the EU EPF workshop Jérôme Boehm 18 May 2010.
Measuring Efficiency CRJS 4466EA. Introduction It is very important to understand the effectiveness of a program, as we have discovered in all earlier.
Overview of Chapter The issues of evidence-based medicine reflect the question of how to apply clinical research literature: Why do disease and injury.
Introduction to Accounting Topic 1 10/26/2015Topic 1: Introduction to accounting.
Risk and Regulatory Policy How do systems of regulatory governance reduce societal risk? Greg Bounds, Administrator Regulatory Policy Division.
EHealth Interoperability – EU Commission activities Dr Octavian Purcarea Unit H1 – ICT for Health Directorate ICT for citizens and businesses DG INFSO.
BMH CLINICAL GUIDELINES IN EUROPE. OUTLINE Background to the project Objectives The AGREE Instrument: validation process and results Outcomes.
NICE - in evidence based commissioning Gateshead Council Gillian Mathews, Implementation Consultant - North 9 September 2011.
Horizon 2020 First reflections Tallinn
THE HIT ADOPTIONINITIATIVE The George Washington University School of Public Health and Health Services The Institute for Health Policy at MGH/Partners.
PGEU Symposium 15 June 2004 Contribution to the Panel discussion Claudio Lepori Member of the AESGP Board AESGP Offices : 7, Avenue de Tervuren, B-1040.
HTA Benefits and Risks Dr Bernard Merkel European Commission.
EARIP Stakeholder Workshop Models and healthcare systems: transferability of best practice across Europe Dr. Aurélien PEREZ European Commission Health.
The ERA-NET TRANSCAN-2, in continuity with the preceding ERA-NET TRANSCAN, aims at linking translational cancer research funding programmes in 15 Member.
Supporting people with active and advanced disease Need better data collection Discussion at MDT – new diagnosis support Identify best practice Early palliative.
The new EC impact assessment: what for? EUROPEAN TRADE UNION CONFEDERATION Sophie Dupressoir.
Evaluation of NRNs Andreas Resch, Evaluation Advisor.
How to measure the impact of R&D on SD ? Laurence Esterle, MD, PhD Cermes and Ifris France Cyprus, 16 – 17 October L. ESTERLE Linking science and.
Footer European Commission eHealth in FP7: The Virtual Physiological Human Joël bacquet Head of sector Health Infrastructure DG Information Society and.
Cost benefit analysis as a methodological perspective for pragmatic FTA – the case of eHealth Dr. Karl A. Stroetmann *, Tom Jones ‡, Alexander Dobrev *,
1 PRIORITY MEDICINES FOR EUROPE AND THE WORLD Barriers to Pharmaceutical Innovation Richard Laing EDM/PAR WHO.
© UEG Presentation by Towards more coordination in health research: a report on the UEG research symposium 16/11/2012 Michael Manns General Assembly.
NMBP : Cross-cutting KETs for diagnostics at the point-of-care co-funded by LEIT-NMBP (DG RTD) and LEIT-ICT (DG CONNECT) Opening 20 Sep 2016 Closing.
Aligning Policy Agendas The case of personalised care and cure for healthy and active ageing Setting the scene for the DG Regio and Flanders Smart Specialisation.
Thematic study on cost analysis of health care provision for migrants and ethnic minorities Conference on Migrants and Health actions funded under the.
The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement no ,
Horizon societal challenge 1 ICT for Health, demographic change and well-being – Work Programme Horizon 2020 Health, Demographic Change.
“ Tools for MoS-Applications ” Assessing modal shift, environmental impact and socio-economic impact Jutta Wolff Institute for Transport Planning and Logistics,
CRITICAL INFRASTRUCTURE RISK ASSESSMENT SUPPORT CIRAS PROJECT OVERVIEW 2nd Stakeholders’ Workshop Aschaffenburg, November, 26th, 2015 Jaime Martín, Project.
Aim: Describe how new health care professionals are deployed
CIRAS FINAL CONFERENCE
Strategies to incorporate pharmacoeconomics into pharmacotherapy
ICT for Health DG Information Society & Media European Commission
Dependability management in automated border control
The International Consortium for Personalised Medicine
Need for a strong Commission for healthcare
Post-2020 discussions 1. State of play of discussions 2. On-going work 3. Questions for debate.
Work Programme 2012 COOPERATION Theme 6 Environment (including climate change) Challenge 6.4 Protecting citizens from environmental hazards European.
Diagnosis of disease M2/D2
Communication & Technology Research
IO4 – Business Intervention Approaches
Presentation transcript:

Who benefits from integrative biomedical research? The socio-economic assessment method of VPHOP Dr. rer. pol. Rainer Thiel, empirica with Karl Stroetman, Veli Stroetmann, Marco Viceconti

IV International Conference on Computational Bioengineering, Bertinoro, September 16-18, Outline 1.Background VPHOP project 2.Methodological challenges to assess integrative biomedical research 3.Three steps of the technology assessment framework 4.Results and future potentials

IV International Conference on Computational Bioengineering, Bertinoro, September 16-18, “Osteoporotic Virtual Physiological Human Project” ●EU funded, to create a patient-specific hypermodel for predicting with ICT-based tools for modelling and simulation of human physiology the absolute risk of bone fracture ●P2 medicine for osteoporosis; directly interrelated with improved clinical outcomes as well as the transformation of diagnosis and treatment of a chronic disease ●Results will be validated not only technically -- impact assessed on organisational, economic and societal issues including clinical practice ●Virtual Physiological Human (VPH) initiative, framework of methods and technologies to investigate the human body as a whole

IV International Conference on Computational Bioengineering, Bertinoro, September 16-18, Organ-level model Cell-level model Constituent-level model Tissue-level model The VPHOP Hypermodel Body-level model Boundary Conditions Bone Remodelling Failure Criterion Constitutive Equation

IV International Conference on Computational Bioengineering, Bertinoro, September 16-18, Assessing the value of VPH health technology Conventional methods (Health Technology Assessment) of limited use, because: ●Very early, experimental phase of technology diffusion ●Radical departure from current type of medical technology ●Likely to transform clinical practice and replace standard of care ●Complex technology integrating a multitude of health technologies

IV International Conference on Computational Bioengineering, Bertinoro, September 16-18, Methodological challenges impact assessment extends into the future – ex-post evaluation methods insufficient two analytically distinct objects of analysis: 1.clinical management of the osteoporotic patient and the hospital change management; 2.disease states and improved health of the patient (fractures avoided and prevention)

IV International Conference on Computational Bioengineering, Bertinoro, September 16-18, Multi-disciplinary, multi-method approach

IV International Conference on Computational Bioengineering, Bertinoro, September 16-18, VPHOP technology impact assessment framework To estimate socio-economic benefits, costs, and related risks, three working steps will be performed: 1.Comparing current and potential new standard of care; prepare detailed clinical pathway and work flows 2. Disease modelling (e.g. Markov cycles) to assess consequences of fractures avoided = tool-box for extracting and generating data (clinical and non-clinical; tangible and non- tangible) 3.Integration and evaluation of data through a scenario- oriented cost benefit analysis

IV International Conference on Computational Bioengineering, Bertinoro, September 16-18, Overview concept and components

IV International Conference on Computational Bioengineering, Bertinoro, September 16-18, Step 1: Comparing current and new standard of care clinical care pathway a tool for (1) collecting basic clinical and economic data (2) estimating the expected impact of the new clinical technology for routine clinical management human and instrumental resources, duration, and costs associated will be attached allows comparison between cost incurred and performance of –(1) current standard of care for osteoporosis –(2) new clinical care with VPHOP services

IV International Conference on Computational Bioengineering, Bertinoro, September 16-18, Step 1: Example of algorithm care pathway for osteoporosis

IV International Conference on Computational Bioengineering, Bertinoro, September 16-18, Step 2: Disease modelling to assess health impact of VPHOP to estimate long term costs and outcomes associated with osteoporosis and benefits of VPHOP services as healthcare intervention improved diagnostics and treatment from the increased predictive power captured as benefits from improved prevention, i.e. associated reduction in costs due to avoided fractures translating expected changes in the patients’ health states into estimates of socio-economic benefits, costs, and related risks

IV International Conference on Computational Bioengineering, Bertinoro, September 16-18, Step 2: Illustration Markov health states osteoporosis

IV International Conference on Computational Bioengineering, Bertinoro, September 16-18, Final step 3: Evaluation through cost benefit analysis results and data from the clinical pathway analysis and disease modelling will be applied into a single CBA identifies and measures total cost and benefits, incl. social costs and benefits, in monetary values discounted costs and benefits can be presented as a cost-benefit ratio options are being evaluated and can be compared in order to identify the most profitable option

IV International Conference on Computational Bioengineering, Bertinoro, September 16-18, Results – Why Impact Assessment? ●Technology development & selection guided by socio-economic ex ante assessment ●Exploitation scenarios, business plans and industrial exploitation derive from socio-economic impact analysis, identifying relevant costs and benefits for all stakeholders ●From the onset configured to permit transfer of the methodology to a broader range of diverse future biomedical integrative research

IV International Conference on Computational Bioengineering, Bertinoro, September 16-18, Acknowledgements We thank the European Commission for their financial and non-financial support! VPHOP is a project co-funded by the European Commission Seventh FRAMEWORK PROGRAMME. The research reported upon in this presentation has either directly or indirectly been supported by the European Commission, Directorate General Information Society and Media, Brussels. The results, analyses and conclusions derived there from reflect solely the views of its authors and of the presenter. The EC is not liable for any use that may be made of the information contained therein.

IV International Conference on Computational Bioengineering, Bertinoro, September 16-18, Further information: Communication & Technology Research Oxfordstr. 2, Bonn, Germany Tel: +49 (2 28) Fax: +49 (2 28)